Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 8/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | USP2 | O75604 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | HAT1 | O14929 | 4/20 | 0.60 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | CASP1 | P29466 | 2/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | TST | Q16762 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864700 | 0.90 | HAT1 (0.53) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL12959321 | 0.89 | KMT2A (0.61) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL863817 | 0.85 | MEN1 (0.64) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL14502896 | 0.84 | KMT2A (0.69) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL864382 | 0.84 | KMT2A (0.65) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL864557 | 0.84 | MEN1 (0.68) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL20906884 | 0.83 | MEN1 (0.71) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL864193 | 0.82 | MEN1 (0.69) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL13966082 | 0.82 | MEN1 (0.66) | KMT2AMEN1KDM4EUSP2MAPT | |
| SCHEMBL11304043 | 0.82 | MEN1 (0.73) | KMT2AMEN1KDM4EUSP2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872081-B1 | SYSTEMS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-2872082-B1 | SYSTEMS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-9707126-B2 | Systems and methods for corneal cross-linking with pulsed light | AVEDRO, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2872081-A2 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | Avedro, INC. (US) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872082-A1 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | Avedro, INC. (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014071408-A1 | SYSTEMS AND METHODS FOR RESHAPING AN EYE FEATURE | AVEDRO, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140066835-A1 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| WO-2014014521-A1 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| US-20130245536-A1 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013059837-A2 | SYSTEMS AND METHODS FOR CORNEAL CROSS-LINKING WITH PULSED LIGHT | AVEDRO, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| CN-102176825-A | Flavin derivatives | BIORELIX PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-0030550-A1 | ANTIHYPERTENSIVE AGENTS AND THEIR USE IN TREATMENT OF HYPERTENSION | TRACHEWSKY, Daniel (US) | 1981-06-24 | — | — | EP | disclosed |
| WO-1980002799-A1 | ANTIHYPERTENSIVE AGENTS AND THEIR USE IN TREATMENT OF HYPERTENSION | TRACHEWSKY D | 1980-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | KMT2A 3259/4885MEN1 4416/4885KDM4E 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.